Repligen to Acquire BioLife Solutions, Adding Market-Leading Biopreservation Media
RGEN sits 36% above its 52-week low of $100.99 on elevated volume (1.9× avg).
Summary
Repligen is acquiring BioLife Solutions, a leader in biopreservation media, in a $1.5 billion deal to expand its cell therapy capabilities. The acquisition adds a critical consumable used in cell and gene therapy manufacturing, complementing Repligen's existing filtration and chromatography portfolio. This follows strong Q1 results where revenue grew 15% to $194 million, showing the company is deploying capital from a position of strength. The deal deepens Repligen's exposure to the high-growth cell therapy market and could accelerate revenue synergies across its bioprocessing platform. BioLife's media is a standard in the industry, and integrating it could strengthen Repligen's single-use solutions offering. Watch for deal terms and expected accretion in the upcoming conference call.
At the time of this announcement, RGEN was trading at $136.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.7B. The 52-week trading range was $100.99 to $175.77. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.